Inga Luckett
Biographic Data
| ID | 10678680 |
|---|---|
| NAME | Inga Luckett |
| GIVEN NAMES | Inga |
| FAMILY NAME | Luckett |
| SIGNATURE | LUCKETT I |
| AFFILIATIONS | From the Departments of Oncology, Radiological Sciences, Biostatistics, Developmental Neurobiology, Pharmaceutical Sciences, Pathology, and Molecular Pharmacology, St Jude Children's Research Hospital; and Department of Pediatrics, The University of Tennessee School of Medicine, Memphis, TN |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 1 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2007 |
| LATEST PUBLICATION YEAR | 2007 |
| H-INDEX | 0 |
Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors
Continuous, orally administered everolimus is well tolerated in children with recurrent or refractory solid tumors and demonstrates similar pharmacokinetic properties to those observed in adults. Everolimus significantly inhibits the mTOR signaling pathway in children at the MTD. The recommended phase II dose in children with solid tumors is 5 mg/m2.
No prominent works on this page.
Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors
Continuous, orally administered everolimus is well tolerated in children with recurrent or refractory solid tumors and demonstrates similar pharmacokinetic properties to those observed in adults. Everolimus significantly inhibits the mTOR signaling pathway in children at the MTD. The recommended phase II dose in children with solid tumors is 5 mg/m2.
Asian American and Pacific Histories (1 works) · Democracy (1 works) · Gender Studies (1 works) · History (1 works) · Law (1 works) · Political science (1 works) · Politics (1 works) · Sociology (1 works) · World War II (1 works)